Needham raises Personalis stock price target on reimbursement wins
#Personalis #Needham #Stock price target #Medicare reimbursement #Biotechnology #MRD testing #PSNL #Cancer diagnostics
📌 Key Takeaways
- Needham raised Personalis price target to $12 from $10 on February 27, 2026
- Personalis stock has gained 113% over the past year, trading at $9.03
- Company secured Medicare reimbursement for breast and lung cancer tests
- Personalis plans to double direct sales force to expand MRD business
- Q4 2025 revenue growth improved to 3% from -44% in Q3
📖 Full Retelling
Needham raised Personalis Inc.'s stock price target to $12 from $10 on Thursday, February 27, 2026, while maintaining a Buy rating on the shares, citing the company's recent Medicare reimbursement victories for cancer tests as the primary reason for the optimistic outlook. The biotechnology company's stock currently trades at $9.03, reflecting a remarkable 113% gain over the past year, though some analysts suggest the shares may be overvalued relative to its Fair Value estimate. Personalis reported fourth-quarter 2025 revenue in line with its preannouncement, though management provided 2026 revenue guidance that fell below consensus expectations. The company demonstrated significant improvement in revenue growth, which increased to 3% in the fourth quarter of 2025 from negative 44% in the third quarter of 2025, with growth across biopharma, clinical diagnostics, and VA MVP segments. Personalis performed 6,183 molecular tests in the fourth quarter of 2025, representing a 41% sequential increase and approximately 330% growth year-over-year. The company has secured Medicare reimbursement for breast cancer and lung cancer tests and is awaiting a decision regarding immunotherapy monitoring coverage. Despite the positive developments, analysts anticipate a sales decline in the current fiscal year and do not expect profitability, though the company maintains more cash than debt on its balance sheet.
🏷️ Themes
Healthcare, Biotechnology, Investment Analysis, Stock Market
📚 Related People & Topics
Biotechnology
Use of living systems and organisms to develop or make useful products
Biotechnology is a multidisciplinary field that involves the integration of natural sciences and engineering sciences in order to achieve the application of organisms and parts thereof for products and services. Specialists in the field are known as biotechnologists. The term biotechnology was first...
Chief Justice of Hungary
Position in Hungary
The chief justice (Hungarian: királyi személynök, Latin: personalis praesentiae regiae in judiciis locumtenens, German: Königliche Personalis) was the personal legal representative of the king of Hungary, who issued decrees of judicial character on behalf of the monarch authenticated with the royal ...
Entity Intersection Graph
Connections for Biotechnology:
🌐
Insider trading
6 shared
🏢
Ginkgo Bioworks
2 shared
🌐
Volatility (finance)
2 shared
🌐
SEC filing
2 shared
👤
William Lewis
1 shared
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Netflix soars after declining to match Paramount Skydance bid for Warner Bros Gold prices steady; on track for strong Feb gains Dorsey’s Block slashes workforce 40% to embrace AI overhaul, shares gain Paramount wins Warner bidding war; Block surges - what’s moving markets (South Africa Philippines Nigeria) Needham raises Personalis stock price target on reimbursement wins By Investing.com Analyst Ratings Published 02/27/2026, 07:07 AM Needham raises Personalis stock price target on reimbursement wins 0 PSNL 8.66% Investing.com - Needham raised its price target on Personalis Inc. (NASDAQ:PSNL) to $12 from $10 on Thursday while maintaining a Buy rating on the shares. The stock currently trades at $9.03, reflecting a remarkable 113% gain over the past year, though InvestingPro analysis suggests the shares may be overvalued relative to its Fair Value estimate. The company’s fourth-quarter 2025 revenue was in line with its preannouncement, according to the firm. Management provided 2026 revenue guidance that was below consensus. Revenue growth improved to 3% in the fourth quarter of 2025 from negative 44% in the third quarter of 2025. Growth from biopharma, clinical diagnostics, and VA MVP all improved. Personalis performed 6,183 molecular tests in the fourth quarter of 2025, up 41% sequentially and approximately 330% year-over-year. The company has been awarded Medicare reimbursement for breast cancer and lung cancer and is awaiting a decision for immunotherapy monitoring.According to InvestingPro Tips, analysts anticipate sales decline in the current year and do not expect profitability, though the company holds more cash than debt on its balance sheet. For deeper insights into PSNL’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities. Needham raised its price target given the additional reimbursement coverage wins fo...
Read full article at source